Navigation Links
Weak spot of parasitic worms attacked to cure tropical diseases
Date:3/21/2014

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.

New funding from the Global Health Innovative Technology Fund will allow scientists from the University of Liverpool's Department of Chemistry, together with colleagues at the Liverpool School of Tropical Medicine and Japanese pharmaceutical company, Eisai, to develop new medication which is targeted at the bacteria Wolbachia.

River blindness (onchocerciasis) and elephantiasis (lymphatic filariasis) are caused by parasitic worms, and previous attempts to cure these diseases have focussed on developing drugs to kill these parasites.

Left untreated, river blindness, where the worms are transmitted by flies, can leave people robbed of their sight, whereas elephantiasis, transmitted by mosquitos, causes extreme swelling in the limbs and genitals.

However, killing the worms too suddenly can cause serious side-effects, so the research team has developed drugs which kill Wolbachia a bacteria which lives in the worms in symbiosis and without which they cannot survive.

Attacking these bacteria causes the worms to die slowly or become sterile. The team, known as the Anti-Wolbachia Consortium (A.WOL), has already shown that a four to six week course of the antibiotic, doxycycline can deplete Wolbachia from parasitic worms to cure infection, which has led to the adoption of this treatment in many areas of the world.

The new funding will allow the creation of drugs which can be used in children and pregnant women and can be effective over the course of a week.

The development of the new drugs was achieved by screening over 60,000 compounds to test their ability to kill Wolbachia. With the new funding, the most promising drug candidates will proceed through advanced rounds of chemical modification and testing to identify compounds that have a good safety and efficacy profiles, ready to move into pre-clinical testing.

Medicinal chemist, Professor Paul O'Neill from the University said: "The relationship between these worms and the bacteria is their weakness.

"By targeting the Wolbachia we can safely remove the worms and the disease, and with a quicker acting drug, we can also develop a medicine which is more useful in areas where resources are scarcer and budgets tighter."


'/>"/>

Contact: Jamie Brown
jamie.brown@liverpool.ac.uk
44-151-794-2248
University of Liverpool
Source:Eurekalert

Related biology news :

1. Europe is joining forces against neglected parasitic diseases
2. Meloidogyne mali: A new invasive plant parasitic nematode in Europe
3. Controlling parasitic worms with genetic selection
4. LSUHSC research identifies new risk factors for parasitic infection
5. Parasitic plants steal genes from their hosts
6. Marine tubeworms need nudge to transition from larvae state
7. Mating is the kiss of death for certain female worms
8. Worms and hot baths: Novel approaches to treating autism
9. Silkworms spin colored silks while on a green dyed-leaf diet
10. Microplastics make marine worms sick
11. Glowing worms illuminate the roots of behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):
(Date:9/18/2017)... ... September 18, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces Bryan Coddington ... , What: Digital Transformation in Medical Device – The Journey to FDA Compliant ...
(Date:9/15/2017)... ... 15, 2017 , ... San Diego based graphene materials and ... round of financing, totaling $600,000. The round was entirely filled by existing ... at a company valuation of $10M. , Grolltex, short for ‘graphene-rolling-technologies’, ...
(Date:9/14/2017)... ... September 14, 2017 , ... DrugDev , ... at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. The ... progressive clinical research leaders for best practice case studies, keynote presentations, lively breakout ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big ... laboratory testing. In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 ...
Breaking Biology Technology: